Literature DB >> 22166581

General practitioners' versus consultants' perspective on indications for paediatric tonsillectomy: current trends.

J Manickavasagam1, S Ali, M S Quraishi.   

Abstract

AIMS: We undertook a study to ascertain what factors general practitioners consider important when referring children for tonsillectomy, and to compare these views with those of consultant ENT surgeons.
METHODS: Web-based questionnaire study.
RESULTS: A total of 141 general practitioners and 146 consultants responded. Tonsillectomy in children was regarded as a useful operation by 65 per cent of general practitioners and 98 per cent of consultant ENT surgeons. This difference was statistically significant (p < 0.001, chi-square test). In 1994, Donnelly et al. found that 92 per cent of general practitioners considered tonsillectomy in children a useful operation; our results were significantly different (p < 0.001, chi-square test).
CONCLUSIONS: There is a good level of awareness and agreement on the currently accepted indications for paediatric tonsillectomy in both groups. However, there were important areas of difference between the two groups with regard to 'glue ear', recurrent ear infections and snoring. Standardised indications for tonsillectomy should be effectively disseminated to general practitioners.

Entities:  

Mesh:

Year:  2011        PMID: 22166581     DOI: 10.1017/S0022215111003070

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  2 in total

1.  A Review and Outcome of Adenoidectomy Performed in Resource Limited Settings.

Authors:  Olajide Toye Gabriel; Olajuyin Oyebanji
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-10-31

2.  Changing indications and socio-demographic determinants of (adeno)tonsillectomy among children in England--are they linked? A retrospective analysis of hospital data.

Authors:  Elizabeth Koshy; Alex Bottle; Joanna Murray; Mike Sharland; Sonia Saxena
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.